KAMADA » INVESTORS » NEWS & EVENTS

NEWS & EVENTS

Latest News

Results of Kamada’s Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients to be Presented at the Upcoming American Diabetes Association’s 78th Scientific Sessions

Jun. 4, 2018

The results from the Company’s Phase 2 trial of Alpha-1 Antitrypsin (AAT) in newly diagnosed type-1 diabetes (T1D) will be presented in an oral session at the 78th Scientific Sessions of the American Diabetes Association (ADA).

Kamada Reports Financial Results for First Quarter of 2018

May. 15, 2018

Kamada today announced financial results for the three months ended
March 31, 2018.


Upcoming Events

Kamada to participate in 78th Scientific Sessions ADA

Jun. 22-26, 2018 / Orlando, Florida

The Scientific Sessions offers researchers and health care professionals an amazing opportunity to share ideas and learn about the significant advances in diabetes research, treatment, and care. Over the course of five days, attendees will receive exclusive access to more than 2,800 original research presentations, take part in provocative and engaging exchanges with leading diabetes experts, and expand professional networks with nearly 13,000 professional attendees from around the world.


Past Event

Kamada to participate in 2018 BIO International Convention

Jun. 4-7, 2018 / Boston, Massachusetts

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. 

The key benefits of attending the 2018 BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry though-leaders with over 500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 74 countries.